Skip to content

    Recently Viewed


      A male scientist in protective glasses and a Johnson & Johnson lab coat writing on a clear whiteboard

      Media Center

      Catch up on the latest Johnson & Johnson news and download the J&J logo and media assets here.

      At Johnson & Johnson our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal.

      Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow. We will combine our science and technology with our determination to create a powerful force of care ... and profoundly impact health for humanity.

      Highlighted press releases

      Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)

      Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to be under clinical development for this serious, life-threatening and rare condition
      Medical technologies
      A colorful example of what 3d cardiac mapping technology produces

      Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium

      Final results from inspIRE study demonstrate 80% freedom from atrial arrhythmia recurrence at 12 months in patients with optimal Pulsed Field Ablation applications First look results from admIRE study suggests similar outcomes
      (Imbruvica) Vials Stock image

      Johnson & Johnson Announces Expansion of IMBRUVICA® (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications

      IMBRUVICA® is now the only Bruton’s tyrosine kinase inhibitor (BTKi) approved with an oral suspension formulation, providing additional flexibility for patients who may have difficulty swallowing tablets or capsules

      Contact Global Media Relations

      Journalists please use the following Johnson & Johnson media relations contacts for inquiries.

      We recommend that if you are on deadline—or if it is after business hours—put ON DEADLINE in the subject of your email. It is also helpful if you are as specific as possible with your request.

      Office Telephone: 732-524-1090
      A person using their smartphone to view the Our Credo page on the Johnson & Johnson website

      Media interviews

      Johnson & Johnson has a state-of-the-art production studio available for media interviews. We have an HD-SDI fiber optic cable connection to the All Mobile Video Gateway in Weehawken, New Jersey. From All Mobile Video Gateway, we can be patched to just about anywhere in the United States accessible by fiber optic cable. Our studio can also send our signal to an AMV uplink which allows for international video connections.

      All press releases

      Press Releases


      1,902 Results
      1,902 results

      In the Media?

      Sign up for Johnson & Johnson company news and press releases delivered right to your inbox.

      Email us at
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.